Geron Corporation (GERN)Â
NASDAQ$1.64
Market Cap
$1.04B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
236 of 924
Rank in Industry
135 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
GERN Insider Trading Activity
GERN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $206,213 | 3 | 38 |
Sells | $8,897,992 | 5 | 62 |
Related Transactions
| Ziegler James | EVP, Chief Commercial Officer | 1 | $160,000 | 0 | $0 | $160,000 |
| Samuels Scott Alan | EVP, Chief Legal Officer | 1 | $24,150 | 0 | $0 | $24,150 |
| SCARLETT JOHN A | Chairman, President and CEO | 1 | $22,063 | 1 | $2.4M | $-2.38M |
| LAWLIS V BRYAN | director | 0 | $0 | 1 | $131,250 | $-131,250 |
| Feller Faye | EVP, Chief Medical Officer | 0 | $0 | 1 | $1.33M | $-1.33M |
| Kapur Anil | EVP, Corp Strategy & CCO | 0 | $0 | 1 | $1.96M | $-1.96M |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer | 0 | $0 | 1 | $3.07M | $-3.07M |
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Insider Activity of Geron Corporation
Over the last 12 months, insiders at Geron Corporation have bought $206,213 and sold $8.9M worth of Geron Corporation stock.
On average, over the past 5 years, insiders at Geron Corporation have bought $88,817 and sold $5.19M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Ziegler James (EVP, Chief Commercial Officer) — $160,000. Samuels Scott Alan (EVP, Chief Legal Officer) — $24,150. SCARLETT JOHN A (Chairman, President and CEO) — $22,063.
The last purchase of 12,500 shares for transaction amount of $22,063 was made by SCARLETT JOHN A (Chairman, President and CEO) on 2025‑02‑27.
List of Insider Buy and Sell Transactions, Geron Corporation
| 2025-02-27 | Ziegler James | EVP, Chief Commercial Officer | 100,000 0.0148% | $1.60 | $160,000 | -3.74% | ||
| 2025-02-27 | Samuels Scott Alan | EVP, Chief Legal Officer | 15,000 0.0022% | $1.61 | $24,150 | -3.74% | ||
| 2025-02-27 | SCARLETT JOHN A | Chairman, President and CEO | 12,500 0.002% | $1.76 | $22,063 | -3.74% | ||
| 2024-07-08 | Sale | GRETHLEIN ANDREW J | EVP, Chief Operating Officer | 674,348 0.1164% | $4.56 | $3.07M | -9.93% | |
| 2024-06-10 | Sale | Kapur Anil | EVP, Corp Strategy & CCO | 421,875 0.0656% | $4.64 | $1.96M | -17.46% | |
| 2024-06-10 | Sale | Feller Faye | EVP, Chief Medical Officer | 287,900 0.0446% | $4.63 | $1.33M | -17.46% | |
| 2024-06-04 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 600,000 0.1014% | $4.00 | $2.4M | +4.26% | |
| 2024-05-15 | Sale | LAWLIS V BRYAN | director | 35,000 0.0057% | $3.75 | $131,250 | +5.38% | |
| 2023-08-24 | O'Farrell Elizabeth G. | director | 13,186 0.0022% | $2.28 | $30,064 | -0.43% | ||
| 2023-05-11 | Sale | LAWLIS V BRYAN | director | 35,000 0.0067% | $3.00 | $105,000 | -20.42% | |
| 2023-05-01 | Sale | Molineaux Susan | director | 35,000 0.0062% | $2.48 | $86,800 | -10.16% | |
| 2023-02-10 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 446,668 0.0818% | $3.00 | $1.34M | -23.26% | |
| 2023-02-09 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 446,666 0.0826% | $3.03 | $1.35M | -23.26% | |
| 2023-02-09 | Sale | GRETHLEIN ANDREW J | EVP, Chief Operating Officer | 384,719 0.0711% | $3.03 | $1.17M | -23.26% | |
| 2023-02-08 | Sale | Bloom Olivia Kyusuk | EVP, Chief Financial Officer | 400,000 0.0742% | $3.08 | $1.23M | -23.61% | |
| 2023-02-08 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 446,666 0.0828% | $3.08 | $1.38M | -23.61% | |
| 2020-08-21 | O'Farrell Elizabeth G. | director | 17,441 0.0056% | $1.73 | $30,173 | 0.00% | ||
| 2020-01-10 | O'Farrell Elizabeth G. | director | 6,000 0.0029% | $1.34 | $8,056 | +23.36% | ||
| 2019-04-09 | Sale | BEHRS MELISSA KELLY | EVP, Chief Business Officer | 241,270 0.1421% | $2.00 | $482,540 | -23.08% | |
| 2018-09-13 | Sale | Spiegel Robert J. | director | 70,000 0.046% | $6.85 | $479,500 | -73.67% |
Total: 129
*Gray background shows transactions not older than one year
Insider Historical Profitability
11.98%
| Ziegler James | EVP, Chief Commercial Officer | 100000 0.0157% | $164,000.00 | 1 | 0 | |
| Samuels Scott Alan | EVP, Chief Legal Officer | 26682 0.0042% | $43,758.48 | 1 | 0 | |
| SCARLETT JOHN A | Chairman, President and CEO | 12500 0.002% | $20,500.00 | 3 | 4 | <0.0001% |
| LAWLIS V BRYAN | director | 0 0% | $0 | 0 | 2 | |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer | 0 0% | $0 | 0 | 2 | |
| Kapur Anil | EVP, Corp Strategy & CCO | 0 0% | $0 | 0 | 1 | |
| Feller Faye | EVP, Chief Medical Officer | 0 0% | $0 | 0 | 1 | |
| MERIX BIOSCIENCE INC | 10 percent owner | 4541100 0.713% | $7.45M | 0 | 7 | |
| GREENWOOD DAVID | President, Interim CEO, CFO | 754031 0.1184% | $1.24M | 0 | 15 | |
| LEBKOWSKI JANE | SVP, Chief Scientific Officer | 568154 0.0892% | $931,772.56 | 0 | 10 | |
| Kelsey Stephen Michael | EVP, R&D Head, CMO | 473122 0.0743% | $775,920.08 | 0 | 4 | |
| EARP DAVID | SVP, Corp Transactions | 467406 0.0734% | $766,545.84 | 0 | 11 | |
| OKARMA THOMAS | President and CEO | 437060 0.0686% | $716,778.40 | 0 | 8 | |
| Spink Katharine E. | SVP Alliance Mgmt & Operations | 328561 0.0516% | $538,840.04 | 0 | 6 | |
| KILEY THOMAS | director | 314059 0.0493% | $515,056.76 | 2 | 0 | <0.0001% |
| BRADBURY DANIEL | director | 142776 0.0224% | $234,152.64 | 1 | 0 | +72.94% |
| Bloom Olivia Kyusuk | EVP, Chief Financial Officer | 74588 0.0117% | $122,324.32 | 0 | 7 | |
| HARLEY CALVIN | VP, CSO Telomerase Tech | 69036 0.0108% | $113,219.04 | 0 | 10 | |
| Spiegel Robert J. | director | 65576 0.0103% | $107,544.64 | 0 | 1 | |
| WALKER JOHN PETER | director | 39119 0.0061% | $64,155.16 | 0 | 1 | |
| Benedetti Fabio M | SVP, Chief Med Off, Oncology | 38060 0.006% | $62,418.40 | 0 | 2 | |
| Hofstaetter Thomas | director | 26564 0.0042% | $43,564.96 | 0 | 1 | |
| O'Farrell Elizabeth G. | director | 26220 0.0041% | $43,000.80 | 3 | 0 | +7.64% |
| BEHRS MELISSA KELLY | EVP, Chief Business Officer | 0 0% | $0 | 0 | 20 | |
| STEIN ROBERT B | director | 0 0% | $0 | 0 | 3 | |
| ROSENFIELD STEPHEN | EVP, Genl Counsel & Secretary | 0 0% | $0 | 0 | 1 | |
| Molineaux Susan | director | 0 0% | $0 | 0 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$54,590,806 | 65 | 21.84% | $1.23B | |
$571,084,134 | 44 | 4.33% | $988.55M | |
$100,002,191 | 42 | 21.48% | $1.22B | |
$530,111,731 | 35 | 8.67% | $1.09B | |
$28,907,358 | 35 | 41.41% | $899.09M | |
$7,598,498 | 27 | 34.68% | $1.17B | |
$169,638,586 | 22 | 30.82% | $1.18B | |
$1,272,896 | 16 | 24.56% | $1.12B | |
$104,137,421 | 15 | 21.28% | $934.08M | |
$50,317,062 | 13 | -3.69% | $852.32M | |
$278,247,340 | 12 | 58.08% | $980.57M | |
$2,834,855 | 9 | 34.92% | $1.11B | |
Geron Corporation (GERN) | $1,229,547 | 7 | 11.98% | $1.04B |
$49,165,200 | 7 | 12.92% | $897.61M | |
$46,235,722 | 6 | -31.77% | $946.15M | |
$7,605,533 | 5 | 17.10% | $894.68M | |
$8,503,480 | 3 | 132.88% | $1.15B | |
$504,640 | 1 | 16.84% | $871.33M | |
$5,000,000 | 1 | -22.84% | $1.08B |
GERN Institutional Investors: Active Positions
| Increased Positions | 157 | +59.7% | 89M | +17.44% |
| Decreased Positions | 96 | -36.5% | 101M | -19.79% |
| New Positions | 66 | New | 32M | New |
| Sold Out Positions | 32 | Sold Out | 52M | Sold Out |
| Total Postitions | 324 | +23.19% | 497M | -2.36% |
GERN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $87,750.00 | 7.83% | 49.86M | +1M | +2.51% | 2024-12-31 |
| Vanguard Group Inc | $59,028.00 | 5.27% | 33.54M | +1M | +3.36% | 2024-12-31 |
| Ra Capital Management, L.P. | $52,817.00 | 4.71% | 30.01M | -2M | -7.05% | 2024-12-31 |
| Vivo Capital, Llc | $47,917.00 | 4.27% | 27.23M | 0 | 0% | 2024-12-31 |
| State Street Corp | $47,798.00 | 4.26% | 27.16M | -2M | -6.23% | 2024-12-31 |
| Janus Henderson Group Plc | $47,665.00 | 4.25% | 27.08M | +5M | +20.02% | 2024-12-31 |
| Holocene Advisors, Lp | $39,065.00 | 3.48% | 22.2M | +4M | +22.15% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $38,368.00 | 3.42% | 21.8M | -7M | -24.5% | 2024-12-31 |
| Fmr Llc | $25,226.00 | 2.25% | 14.33M | -646,273 | -4.32% | 2024-12-31 |
| Goldman Sachs Group Inc | $23,954.00 | 2.14% | 13.61M | -4M | -24.14% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.